Stock Events

Stock Events

MiNK Therapeutics 

€9.65
49
-€0.15-1.53% Wednesday 06:00

Statistics

Day High
9.65
Day Low
9.65
52W High
11.8
52W Low
7.55
Volume
-
Avg. Volume
-
Mkt Cap
49.24M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13NovExpected
Q1 2026
Q2 2026
Next
-0.66
-0.54
-0.42
-0.3
Expected EPS
-0.30128
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-10.83MNet Income

Analyst Ratings

26.56Average Price Target
The highest estimate is 26.56.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6Q40.MU. It's not an investment recommendation.
NVIDIA
14
NVDA
Agenus
14
AGEN
Amazon
13
AMZN
Microsoft
12
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is involved in the development of programmed cellular immunotherapies, including NK cell-based therapies, making it a direct competitor in the cell therapy market.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, has a strong presence in the cell therapy space for oncology, competing with MiNK's approach to cancer treatment.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics focuses on allogeneic CAR T-cell therapies, competing in the broader cell therapy market for cancer, which includes MiNK's NK cell therapies.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is engaged in gene editing and cell therapy, including CAR T-cell therapies, competing in the innovative cancer treatment space with MiNK.
NovoCure
NVCR
Mkt Cap2.08B
NovoCure operates in the oncology space with a novel tumor treating fields (TTF) technology, offering a different approach to cancer treatment but still competing for the same patient population as MiNK.

About

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
Show more...
CEO
Jennifer S. Buell
Employees
15
Country
United States
ISIN
US6036932019
WKN
000A40ZAV

Listings

F
DE
6Q40.F
MU
DE
6Q40.MU
XNAS
US
INKT
BOATS
BOATS
INKT.BOATS

0 Comments

Share your thoughts

FAQ

What is MiNK Therapeutics stock price today?▼
The current price of 6Q40.MU is €9.65 EUR — it has decreased by -1.53% in the past 24 hours. Watch MiNK Therapeutics stock price performance more closely on the chart.
What is MiNK Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange MiNK Therapeutics stocks are traded under the ticker 6Q40.MU.
What is MiNK Therapeutics market cap?▼
Today MiNK Therapeutics has the market capitalization of 49.24M
When is the next MiNK Therapeutics earnings date?▼
MiNK Therapeutics is going to release the next earnings report on November 13, 2026.
What were MiNK Therapeutics earnings last quarter?▼
6Q40.MU earnings for the last quarter are -0.54 EUR per share, whereas the estimation was -0.52 EUR resulting in a -3.33% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is MiNK Therapeutics revenue for the last year?▼
MiNK Therapeutics revenue for the last year amounts to 0 EUR.
What is MiNK Therapeutics net income for the last year?▼
6Q40.MU net income for the last year is -10.83M EUR.
How many employees does MiNK Therapeutics have?▼
As of September 05, 2026, the company has 15 employees.
In which sector is MiNK Therapeutics located?▼
MiNK Therapeutics operates in the Health & Wellness sector.
When did MiNK Therapeutics complete a stock split?▼
The last stock split for MiNK Therapeutics was on January 28, 2025 with a ratio of 1:10.
Where is MiNK Therapeutics headquartered?▼
MiNK Therapeutics is headquartered in NEW YORK, United States.